MetrioPharm AG, a Switzerland-based biotech company developing drugs for inflammatory and infectious diseases, has named four new members to its board in a realignment initiated by the outgoing board of directors. The new members are Harald Fricke, Martina Muttke, Stephan Rietiker and Jörg Zwicker. The board members Jörg Gruber and Christoph von Moos will remain on the board. Among them, the new members bring extensive experience in the biotech and pharmaceutical industry, especially in research and development, pharmaceutical strategy and regulatory affairs. Outgoing members included former chairman Rudolf Stäger. The new board will be responsible for the further clinical development of MetrioPharm’s pipeline of disease-specific drug combinations targeting inflammatory, autoimmune, and degenerative diseases, as well as treatments for infectious diseases such as COVID-19.
MetrioPharm announced the appointments on 17 April 2025.
Copyright 2025 Evernow Publishing Ltd.